ACOR Stock Pops on FDA Nod

The stock is set to snap a four-day losing streak

Digital Content Manager
Dec 24, 2018 at 11:32 AM
facebook X logo linkedin

Acorda Therapeutics (NASDAQ:ACOR) shares are up 5% at $13.59 today, lifted by Friday's late-breaking news that the Food and Drug Administration (FDA) approved its new Parkinson's drug. The inhalable treatment, INBRIJA, is expected out during the first quarter of 2019. Today's rally for ACOR is pulling it out of the gutter -- the stock ended last week at 12-year lows -- and could help the shares snap their four-day losing streak. 

That losing streak and multi-year lows capped off the serious pummeling ACOR has taken since an early September sell-off in which the security lost nearly a quarter of its value in a single day. The shares have since encountered resistance at the $20-21 area. Down 36.7% year-to-date, ACOR is headed for its second-worst year on record. 

Analysts are primarily cautious, with five of eight issuing ACOR a tepid "hold" rating. However, two still see it as a "strong buy," and only one slapped it with a "strong sell." What's more, the 12-month consensus price target of $21.89 still represents a 61% premium to the stock's current levels. 

ACOR's recent slump sparked some bearish speculation, with short interest up 13.3% in the past two reporting periods. That means today's rally could be the result of a short squeeze among some of the weaker bearish hands, as short interest now represents a whopping 20.7% of the stock's available float. Plus, at ACOR's average daily trading volume, it would take almost a month to repurchase all of these bearish bets -- a catalyst for additional tailwinds should pessimism begin to unwind. 


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI